Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC is a leading global pharmaceutical company specializing in the development, manufacturing, and distribution of high-quality generic, branded, and specialty medicines. Founded over 45 years ago, it focuses on making essential medications accessible, particularly through its extensive operations in the Middle East and North Africa (MENA) region, as well as North America and Europe. The company operates 29 manufacturing plants worldwide, including 23 in MENA, producing a broad portfolio of injectable, oral, nasal, inhalable, and biosimilar products targeting key therapeutic areas such as oncology, anti-infectives, cardiovascular, antidiabetics, respiratory, central nervous system, gastrointestinal, and antibiotics for bacterial infections. Hikma integrates access-to-medicine strategies into its business model, participating in government tenders, forming licensing partnerships like those for trastuzumab and rituximab biosimilars, and investing in local capacity building, such as new injectable sites in Algeria and Morocco. With robust quality systems, stringent regulatory compliance at multiple sites, and adaptive R&D for low- and middle-income countries, including stable formulations for LMICs, Hikma plays a vital role in addressing non-communicable and communicable diseases, enhancing public sector supply, and improving global health equity through reliable, affordable pharmaceuticals.

Want to understand how we rate dividend safety? Read our full methodology